Impact of response evaluation for resectable esophageal adenocarcinoma - A retrospective cohort study

International Journal of Surgery

Volumn 12, Issue 10, 2014, Pages 1025-1030

  Bachmann, R ^a   Bachmann, J ^b   Hungbauer, A ^a   Schmehl, J ^a   Sitzmann, G ^a   Konigsrainer A ^a   Ladurner, R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Esophageal carcinoma; Histopathological regression grading; Neoadjuvant chemotherapy; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ANASTOMOSIS; ESOPHAGOJEJUNOSTOMY; ESOPHAGUS ANASTOMOSIS; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE TREATMENT; RADICAL RESECTION; RETROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; STOMACH SURGERY; SURVIVAL RATE; SURVIVAL TIME; TOTAL STOMACH RESECTION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANASTOMOSIS; ESOPHAGEAL NEOPLASMS; GASTRECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURGERY; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANASTOMOSIS, SURGICAL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84908006233     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2014.08.400     Document Type: Article

References (18)

1. Pera M., Manterola C., et al. Epidemiology of esophageal adeno-carcinoma. J.Surg. Oncol. 2005, 92:151-159.
2. Siewert J.R., Feith M., Stein H.J. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J.Surg. Oncol. 2005, 90:139-146.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: Cancer J. Clin. 2013, 63(1):11-30.
4. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J. Clin. 2011, 61(4):212-236.
5. Siewert J., Stein H. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection. Dis. Esophagus 1996, 9:173-182.
6. Cunningham D., Allum W., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. NEngl. J. Med. 2006, 355:11-20.
7. Lordick F. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res. 2012, 196:201-211.
8. 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann. Surg. 2013 Jul, 258(1):66-76.
9. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 1998, 85(11):1457-1459.
10. Siewert J.R., Stein H.J., Feith M. Adenocarcinoma of the esophago-gastric junction. Scand. J. Surg. 2006, 95(4):260-269.
11. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
12. Becker K., Mueller J.D., Schulmacher C., Ott K., Fink U., Busch R., Bottcher K., Siewert J.R., Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98(7):1521-1530.
13. Allum W.H., Stenning S.P., Bancewicz Jetal Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J.Clin. Oncol. 2009, 27(30):5062-5067.
14. Lordick F., Ott K., Krause B.J., Weber W.A., Becker K., Stein H.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007, 8:797-805.
15. Palmes D., Brüwer M., Bader F.G., Betzler M., Becker H., Bruch H.P., et al. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch. Surg. 2011 Aug, 396(6):857-866. German Advanced Surgical Treatment Study Group.
16. Rebollo Aguirre A.C., Ramos-Font C., Villegas Portero R., et al. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann. Surg. 2009, 250:247-254.
17. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J.Clin. Oncol. 2011, 29:1715-1721.
18. Stahl M., Walz M.K., Stuschke M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J.Clin. Oncol. 2009, 27:851-856.